Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Cash (2016 - 2025)

Ptc Therapeutics has reported Change in Cash over the past 14 years, most recently at $312.0 million for Q4 2025.

  • Quarterly results put Change in Cash at $312.0 million for Q4 2025, up 22.11% from a year ago — trailing twelve months through Dec 2025 was $203.0 million (up 9.72% YoY), and the annual figure for FY2025 was $203.0 million, up 9.72%.
  • Change in Cash for Q4 2025 was $312.0 million at Ptc Therapeutics, up from -$346.8 million in the prior quarter.
  • Over the last five years, Change in Cash for PTCT hit a ceiling of $700.5 million in Q1 2025 and a floor of -$462.8 million in Q2 2025.
  • Median Change in Cash over the past 5 years was -$4.6 million (2021), compared with a mean of $39.1 million.
  • Biggest five-year swings in Change in Cash: soared 175514.0% in 2022 and later tumbled 545.34% in 2025.
  • Ptc Therapeutics' Change in Cash stood at -$100000.0 in 2021, then soared by 175514.0% to $175.4 million in 2022, then surged by 144.49% to $428.9 million in 2023, then crashed by 40.42% to $255.5 million in 2024, then increased by 22.11% to $312.0 million in 2025.
  • The last three reported values for Change in Cash were $312.0 million (Q4 2025), -$346.8 million (Q3 2025), and -$462.8 million (Q2 2025) per Business Quant data.